Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 715

1.

Rituximab as maintenance treatment for systemic Lupus Erythematosus: a multicentre observational study of 147 patients.

Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, Emmi G, Moroni G, Sinico RA, Messa P, Hall F, Vaglio A, Gallieni M, Jayne DR.

Arthritis Rheumatol. 2019 May 18. doi: 10.1002/art.40932. [Epub ahead of print]

PMID:
31102498
2.

HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated with HIV DNA and HIV-specific T Cell Responses.

Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT; and the ACTG 5321 team.

J Acquir Immune Defic Syndr. 2019 Apr 23. doi: 10.1097/QAI.0000000000002080. [Epub ahead of print]

PMID:
31045647
3.

High intake of dietary fructose in overweight/obese teenagers associated with depletion of Eubacterium and Streptococcus in gut microbiome.

Jones RB, Alderete TL, Kim JS, Millstein J, Gilliland FD, Goran MI.

Gut Microbes. 2019 Apr 16:1-8. doi: 10.1080/19490976.2019.1592420. [Epub ahead of print]

PMID:
30991877
4.

HIV Controllers Exhibit Effective CD8+ T Cell Recognition of HIV-1-Infected Non-activated CD4+ T Cells.

Monel B, McKeon A, Lamothe-Molina P, Jani P, Boucau J, Pacheco Y, Jones RB, Le Gall S, Walker BD.

Cell Rep. 2019 Apr 2;27(1):142-153.e4. doi: 10.1016/j.celrep.2019.03.016.

5.

Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Takata H, Kessing C, Sy A, Lima N, Sciumbata J, Mori L, Jones RB, Chomont N, Michael NL, Valente S, Trautmann L.

J Virol. 2019 May 15;93(11). pii: e02248-18. doi: 10.1128/JVI.02248-18. Print 2019 Jun 1.

PMID:
30918072
6.

Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.

McClure ME, Wason J, Gopaluni S, Tieu J, Smith RM, Jayne DR, Jones RB.

J Clin Rheumatol. 2019 Mar 20. doi: 10.1097/RHU.0000000000001030. [Epub ahead of print]

PMID:
30896460
7.

Response to: 'MYCYC, unravelling the long road ahead in ANCA-associated vasculitis' by Jain et al.

Harper L, Jones RB.

Ann Rheum Dis. 2019 Mar 20. pii: annrheumdis-2019-215254. doi: 10.1136/annrheumdis-2019-215254. [Epub ahead of print] No abstract available.

PMID:
30894344
9.

Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion.

Pinzone MR, VanBelzen DJ, Weissman S, Bertuccio MP, Cannon L, Venanzi-Rullo E, Migueles S, Jones RB, Mota T, Joseph SB, Groen K, Pasternak AO, Hwang WT, Sherman B, Vourekas A, Nunnari G, O'Doherty U.

Nat Commun. 2019 Feb 13;10(1):728. doi: 10.1038/s41467-019-08431-7.

10.

Current challenges and recent advances in the search for a cure for HIV.

Jones RB.

J Int AIDS Soc. 2019 Feb;22(2):e25248. doi: 10.1002/jia2.25248. No abstract available.

11.

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, Burns A, Griffith M, Galliford J, Levy JB, Cairns TD, Gopaluni S, Jones RB, Jayne D, Little MA, Pusey CD, Salama AD.

Rheumatology (Oxford). 2019 Feb 1;58(2):373. doi: 10.1093/rheumatology/kez001. No abstract available.

PMID:
30690635
12.

Effect of Tuberosity Healing on Clinical Outcomes in Elderly Patients Treated With a Reverse Shoulder Arthroplasty for 3- and 4-Part Proximal Humerus Fractures.

Simovitch RW, Roche CP, Jones RB, Routman HD, Marczuk Y, Wright TW, Zuckerman JD.

J Orthop Trauma. 2019 Feb;33(2):e39-e45. doi: 10.1097/BOT.0000000000001348.

PMID:
30688837
13.

Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs.

Flerin NC, Bardhi A, Zheng JH, Korom M, Folkvord J, Kovacs C, Benko E, Truong R, Mota T, Connick E, Jones RB, Lynch RM, Goldstein H.

J Virol. 2019 Mar 5;93(6). pii: e02051-18. doi: 10.1128/JVI.02051-18. Print 2019 Mar 15.

PMID:
30626677
14.

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.

Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, Cid MC, Dahlsveen K, de Zoysa J, Espigol-Frigolé G, Lanyon P, Peh CA, Tesar V, Vaglio A, Walsh M, Walsh D, Walters G, Harper L, Jayne D; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2019 Mar;78(3):399-405. doi: 10.1136/annrheumdis-2018-214245. Epub 2019 Jan 5.

PMID:
30612116
15.

Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Alatrash G, Kidwell KM, Thall PF, Di Stasi A, Chen J, Zope M, Crain AK, Champlin RE, Popat U, Shpall EJ, Jones RB, Andersson BS.

Bone Marrow Transplant. 2018 Dec 10. doi: 10.1038/s41409-018-0405-0. [Epub ahead of print]

PMID:
30532055
16.

Publisher Correction: Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Nov;563(7733):E33. doi: 10.1038/s41586-018-0611-3.

PMID:
30315222
17.

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.

JCI Insight. 2018 Oct 4;3(19). pii: 122673. doi: 10.1172/jci.insight.122673.

18.

Multicentred randomised controlled trial of an augmented exercise referral scheme using web-based behavioural support in individuals with metabolic, musculoskeletal and mental health conditions: protocol for the e-coachER trial.

Ingram W, Webb D, Taylor RS, Anokye N, Yardley L, Jolly K, Mutrie N, Campbell JL, Dean SG, Greaves C, Steele M, Lambert JD, McAdam C, Jane B, King J, Jones RB, Little P, Woolf A, Erwin J, Charles N, Terry RH, Taylor AH; Trial Steering Committee.

BMJ Open. 2018 Sep 21;8(9):e022382. doi: 10.1136/bmjopen-2018-022382.

19.

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Pepper RJ, McAdoo SP, Moran SM, Kelly D, Scott J, Hamour S, Burns A, Griffith M, Galliford J, Levy JB, Cairns TD, Gopaluni S, Jones RB, Jayne D, Little MA, Pusey CD, Salama AD.

Rheumatology (Oxford). 2019 Feb 1;58(2):260-268. doi: 10.1093/rheumatology/key288.

PMID:
30239910
20.

Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Sep;561(7723):E20-E28. doi: 10.1038/s41586-018-0495-2. Epub 2018 Sep 19. No abstract available. Erratum in: Nature. 2018 Nov;563(7733):E33.

21.

Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.

Ren Y, Korom M, Truong R, Chan D, Huang SH, Kovacs CC, Benko E, Safrit JT, Lee J, Garbán H, Apps R, Goldstein H, Lynch RM, Jones RB.

J Virol. 2018 Nov 12;92(23). pii: e00895-18. doi: 10.1128/JVI.00895-18. Print 2018 Dec 1.

22.

Short Communication: Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy.

Bachtel ND, Beckerle GA, Mota TM, Rougvie MM, Raposo RAS, Jones RB, Nixon DF, Apps R.

AIDS Res Hum Retroviruses. 2019 Jan;35(1):108-111. doi: 10.1089/AID.2018.0162. Epub 2018 Oct 16.

PMID:
30198299
23.

Phylogenetic approach to recover integration dates of latent HIV sequences within-host.

Jones BR, Kinloch NN, Horacsek J, Ganase B, Harris M, Harrigan PR, Jones RB, Brockman MA, Joy JB, Poon AFY, Brumme ZL.

Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8958-E8967. doi: 10.1073/pnas.1802028115. Epub 2018 Sep 5.

24.

HLA-C downregulation by HIV-1 adapts to host HLA genotype.

Bachtel ND, Umviligihozo G, Pickering S, Mota TM, Liang H, Del Prete GQ, Chatterjee P, Lee GQ, Thomas R, Brockman MA, Neil S, Carrington M, Bwana B, Bangsberg DR, Martin JN, Kallas EG, Donini CS, Cerqueira NB, O'Doherty UT, Hahn BH, Jones RB, Brumme ZL, Nixon DF, Apps R.

PLoS Pathog. 2018 Sep 4;14(9):e1007257. doi: 10.1371/journal.ppat.1007257. eCollection 2018 Sep.

25.

Effectiveness of six core strategies based on trauma informed care in reducing seclusions and restraints at a child and adolescent psychiatric hospital.

Azeem M, Aujla A, Rammerth M, Binsfeld G, Jones RB.

J Child Adolesc Psychiatr Nurs. 2017 Nov;30(4):170-174. doi: 10.1111/jcap.12190.

PMID:
30129244
26.

Greater Microbial Translocation and Vulnerability to Metabolic Disease in Healthy Aged Female Monkeys.

Wilson QN, Wells M, Davis AT, Sherrill C, Tsilimigras MCB, Jones RB, Fodor AA, Kavanagh K.

Sci Rep. 2018 Jul 27;8(1):11373. doi: 10.1038/s41598-018-29473-9.

27.

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure.

Clutton GT, Jones RB.

Front Immunol. 2018 Jun 22;9:1452. doi: 10.3389/fimmu.2018.01452. eCollection 2018. Review.

28.

Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.

Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, Smith RM, Jayne DRW.

Ann Rheum Dis. 2018 Oct;77(10):1440-1447. doi: 10.1136/annrheumdis-2017-212861. Epub 2018 Jun 27.

29.

Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):769-777. doi: 10.1089/AID.2018.0098. Epub 2018 Aug 10.

PMID:
29926732
30.

Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.

Banham GD, Flint SM, Torpey N, Lyons PA, Shanahan DN, Gibson A, Watson CJE, O'Sullivan AM, Chadwick JA, Foster KE, Jones RB, Devey LR, Richards A, Erwig LP, Savage CO, Smith KGC, Henderson RB, Clatworthy MR.

Lancet. 2018 Jun 30;391(10140):2619-2630. doi: 10.1016/S0140-6736(18)30984-X. Epub 2018 Jun 14.

PMID:
29910042
31.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

Patel S, Chorvinsky E, Albihani S, Cruz CR, Jones RB, Shpall EJ, Margolis DM, Ambinder RF, Bollard CM.

Mol Ther. 2018 Jun 6;26(6):1435-1446. doi: 10.1016/j.ymthe.2018.04.009. Epub 2018 Apr 12.

32.

An Aberrant Microbiota is not Strongly Associated with Incidental Colonic Diverticulosis.

Jones RB, Fodor AA, Peery AF, Tsilimigras MCB, Winglee K, McCoy A, Sioda M, Sandler RS, Keku TO.

Sci Rep. 2018 Mar 21;8(1):4951. doi: 10.1038/s41598-018-23023-z.

33.

Inter-niche and inter-individual variation in gut microbial community assessment using stool, rectal swab, and mucosal samples.

Jones RB, Zhu X, Moan E, Murff HJ, Ness RM, Seidner DL, Sun S, Yu C, Dai Q, Fodor AA, Azcarate-Peril MA, Shrubsole MJ.

Sci Rep. 2018 Mar 7;8(1):4139. doi: 10.1038/s41598-018-22408-4.

34.

Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.

Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1602-1609. doi: 10.1016/j.bbmt.2018.02.020. Epub 2018 Mar 2.

PMID:
29501779
35.
36.

Probiotic supplementation increases obesity with no detectable effects on liver fat or gut microbiota in obese Hispanic adolescents: a 16-week, randomized, placebo-controlled trial.

Jones RB, Alderete TL, Martin AA, Geary BA, Hwang DH, Palmer SL, Goran MI.

Pediatr Obes. 2018 Nov;13(11):705-714. doi: 10.1111/ijpo.12273. Epub 2018 Feb 28.

37.

The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.

Jones RB, Dorsett KA, Hjelmeland AB, Bellis SL.

J Biol Chem. 2018 Apr 13;293(15):5659-5667. doi: 10.1074/jbc.RA117.001194. Epub 2018 Feb 23.

38.

Prospective Trials Are Required to Alter Practice for Follow-up Blood Cultures for Gram-Negative Bacilli Bacteremia.

Jones RB, Paruchuri A, Shah SS.

Clin Infect Dis. 2018 Jul 2;67(2):315-316. doi: 10.1093/cid/ciy070. No abstract available.

PMID:
29394336
39.

The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles.

Webb GM, Li S, Mwakalundwa G, Folkvord JM, Greene JM, Reed JS, Stanton JJ, Legasse AW, Hobbs T, Martin LD, Park BS, Whitney JB, Jeng EK, Wong HC, Nixon DF, Jones RB, Connick E, Skinner PJ, Sacha JB.

Blood Adv. 2018 Jan 23;2(2):76-84. doi: 10.1182/bloodadvances.2017012971.

40.

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Huang SH, Ren Y, Thomas AS, Chan D, Mueller S, Ward AR, Patel S, Bollard CM, Cruz CR, Karandish S, Truong R, Macedo AB, Bosque A, Kovacs C, Benko E, Piechocka-Trocha A, Wong H, Jeng E, Nixon DF, Ho YC, Siliciano RF, Walker BD, Jones RB.

J Clin Invest. 2018 Feb 1;128(2):876-889. doi: 10.1172/JCI97555. Epub 2018 Jan 22.

41.

Stem Cell Transplantation and Informatics: Current Considerations.

Jones RB, Martinez C, Majhail NS, Prestegaard M, Maiers M, Horwitz M, Komanduri K.

Biol Blood Marrow Transplant. 2018 Apr;24(4):659-665. doi: 10.1016/j.bbmt.2017.12.792. Epub 2017 Dec 27. Review.

42.

Exposure to traffic-related air pollution and the composition of the gut microbiota in overweight and obese adolescents.

Alderete TL, Jones RB, Chen Z, Kim JS, Habre R, Lurmann F, Gilliland FD, Goran MI.

Environ Res. 2018 Feb;161:472-478. doi: 10.1016/j.envres.2017.11.046.

43.

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.

Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB.

PLoS Pathog. 2017 Sep 20;13(9):e1006629. doi: 10.1371/journal.ppat.1006629. eCollection 2017 Sep.

44.

Identification of Novel Protein Expression Changes Following Cisplatin Treatment and Application to Combination Therapy.

Stark AL, Madian AG, Williams SW, Chen V, Wing C, Hause RJ Jr, To LA, Gill AL, Myers JL, Gorsic LK, Ciaccio MF, White KP, Jones RB, Dolan ME.

J Proteome Res. 2017 Nov 3;16(11):4227-4236. doi: 10.1021/acs.jproteome.7b00576. Epub 2017 Sep 29.

PMID:
28902521
45.

Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype.

Mohammad AJ, Mortensen KH, Babar J, Smith R, Jones RB, Nakagomi D, Sivasothy P, Jayne DRW.

J Rheumatol. 2017 Oct;44(10):1458-1467. doi: 10.3899/jrheum.161224. Epub 2017 Aug 1.

PMID:
28765242
46.

Glycinol enhances osteogenic differentiation and attenuates the effects of age on mesenchymal stem cells.

Strong AL, Jones RB Jr, Glowacki J, Boue SM, Burow ME, Bunnell BA.

Regen Med. 2017 Jul;12(5):513-524. doi: 10.2217/rme-2016-0148. Epub 2017 Jul 18.

PMID:
28718749
47.

High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.

Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M.

Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15.

48.

MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines.

Rohrbach TD, Jones RB, Hicks PH, Weaver AN, Cooper TS, Eustace NJ, Yang ES, Jarboe JS, Anderson JC, Willey CD.

Oncol Lett. 2017 Mar;13(3):1216-1222. doi: 10.3892/ol.2016.5550. Epub 2016 Dec 29.

49.

Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC.

Cell Host Microbe. 2017 Apr 12;21(4):494-506.e4. doi: 10.1016/j.chom.2017.03.008.

50.

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.

Gopaluni S, Smith RM, Lewin M, McAlear CA, Mynard K, Jones RB, Specks U, Merkel PA, Jayne DR; RITAZAREM Investigators.

Trials. 2017 Mar 7;18(1):112. doi: 10.1186/s13063-017-1857-z.

Supplemental Content

Loading ...
Support Center